PDCD1 and cancer: In turn, cancer-related inflammation with related metabolic and nutritional changes can contribute to immunosuppression by different mechanisms [25,26,27] and can thus considerably affect the antineoplastic immune response and PD-1/PD-L1 inhibitor efficacy, involving poorer outcomes in patients with cancer cachexia treated with these agents.